

55

36. The nucleic acid-lipid particle in accordance with claim 10, wherein said DSPC comprises about 10 mol % of the total lipid present in said particle.

37. The nucleic acid-lipid particle in accordance with claim 4, wherein said cationic lipid comprises from about 2 mol % to about 60 mol % of the total lipid present in said particle.

38. The nucleic acid-lipid particle in accordance with claim 4, wherein said non-cationic lipid comprises dipalmitoylphosphatidylcholine (DPPC).

39. The nucleic acid-lipid particle in accordance with claim 4, wherein said non-cationic lipid comprises DPPC and cholesterol.

40. The siRNA molecule in accordance with claim 1, wherein said siRNA molecule comprises 3' overhangs of about 1 to about 4 nucleotides on one or both sides of the double-stranded sequence.

41. The siRNA molecule in accordance with claim 1, wherein said siRNA molecule comprises at least one modified nucleotide.

56

42. The siRNA molecule in accordance with claim 1, wherein said siRNA molecule comprises at least one modified nucleotide in one or both strands of the double-stranded sequence.

43. The siRNA molecule in accordance with claim 1, wherein said siRNA molecule comprises at least one 2'-O-methyl (2'OMe) nucleotide.

44. The siRNA molecule in accordance with claim 1, wherein said siRNA molecule comprises at least one 2'OMe nucleotide selected from the group consisting of a 2'OMe-guanosine nucleotide, 2'OMe-uridine nucleotide, 2'OMe-adenosine nucleotide, 2'OMe-cytosine nucleotide, and mixtures thereof.

45. The nucleic acid-lipid particle in accordance with claim 11, wherein said conjugated lipid that inhibits aggregation of particles comprises from about 0.5 mol % to about 20 mol % of the total lipid present in said particle.

\* \* \* \* \*